Literature DB >> 7499413

Identification of the binding domain for secretory phospholipases A2 on their M-type 180-kDa membrane receptor.

J P Nicolas1, G Lambeau, M Lazdunski.   

Abstract

The rabbit muscle (M)-type receptor for secretory phospholipases A2 (sPLA2s) has a large extracellular domain of 1394 amino acids, composed of an N-terminal cysteine-rich domain, a fibronectin-like type II domain, and eight carbohydrate recognition domains (CRDs). It is thought to mediate some of the physiological effects of mammalian sPLA2s, including vascular smooth muscle contraction and cell proliferation, and is able to internalize sPLA2s. Here, we show by site-directed mutagenesis that OS1, a snake venom sPLA2, binds to the receptor via its CRDs and that deletion of CRD 5 completely abolishes the binding of sPLA2s. Moreover, a receptor lacking all CRDs but CRD 5 was still able to bind OS1 although with a lower affinity. Deletion of CRDs 4 and 6, surrounding the CRD 5, slightly reduced the affinity for OS1, thus suggesting that these CRDs are also involved in the binding of OS1. The M-type sPLA2 receptor and the macrophage mannose receptor are homologous and are predicted to share the same tertiary structure. p-Aminophenyl-alpha-D-mannopyranoside bovine serum albumin, a known ligand of the macrophage mannose receptor, binds to the M-type sPLA2 receptor essentially via CRDs 3-6.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499413     DOI: 10.1074/jbc.270.48.28869

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  The macrophage/endothelial cell mannose receptor cDNA encodes a protein that binds oligosaccharides terminating with SO4-4-GalNAcbeta1,4GlcNAcbeta or Man at independent sites.

Authors:  D Fiete; M C Beranek; J U Baenziger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner.

Authors:  Jun Saegusa; Nobuaki Akakura; Chun-Yi Wu; Case Hoogland; Zi Ma; Kit S Lam; Fu-Tong Liu; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

3.  Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1.

Authors:  Masaaki Fujita; Kan Zhu; Chitose K Fujita; Min Zhao; Kit S Lam; Mark J Kurth; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2014-11-14       Impact factor: 5.157

4.  Molecular modeling of Gly80 and Ser80 variants of human group IID phospholipase A2 and their receptor complexes: potential basis for weight loss in chronic obstructive pulmonary disease.

Authors:  Mohd Imran Khan; Ashish Kumar Gupta; Domada Ratna Kumar; Manoj Kumar; Abdul Samarth Ethayathulla; Gururao Hariprasad
Journal:  J Mol Model       Date:  2016-09-01       Impact factor: 1.810

5.  Two phospholipase A2 inhibitors from the plasma of Cerrophidion (Bothrops) godmani which selectively inhibit two different group-II phospholipase A2 myotoxins from its own venom: isolation, molecular cloning and biological properties.

Authors:  S Lizano; Y Angulo; B Lomonte; J W Fox; G Lambeau; M Lazdunski; J M Gutiérrez
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

6.  Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.

Authors:  N D Quach; J N Mock; N E Scholpa; M W Eggert; C Payré; G Lambeau; R D Arnold; B S Cummings
Journal:  Mol Pharm       Date:  2014-09-22       Impact factor: 4.939

Review 7.  Alpha-type phospholipase A2 inhibitors from snake blood.

Authors:  Norival A Santos-Filho; Claudia T Santos
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2017-03-23

Review 8.  Secreted Phospholipases A2 - not just Enzymes: Revisited.

Authors:  Adrijan Ivanušec; Jernej Šribar; Igor Križaj
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

9.  A New Approach to Inhibiting Triple-Negative Breast Cancer: In Vitro, Ex Vivo and In Vivo Antiangiogenic Effect of BthTx-II, a PLA2-Asp-49 from Bothrops jararacussu Venom.

Authors:  Fernanda Van Petten de Vasconcelos Azevedo; Daiana Silva Lopes; Mariana Alves Pereira Zóia; Lucas Ian Veloso Correia; Natieli Saito; Belchiolina Beatriz Fonseca; Lorena Polloni; Samuel Cota Teixeira; Luiz Ricardo Goulart; Veridiana de Melo Rodrigues Ávila
Journal:  Biomolecules       Date:  2022-02-04

10.  Treatment of Mouse Sperm with a Non-Catalytic Mutant of PLA2G10 Reveals That PLA2G10 Improves In Vitro Fertilization through Both Its Enzymatic Activity and as Ligand of PLA2R1.

Authors:  Roland Abi Nahed; Magali Dhellemmes; Christine Payré; Emilie Le Blévec; Jean-Philippe Perrier; Sylviane Hennebicq; Jessica Escoffier; Pierre F Ray; Corinne Loeuillet; Gérard Lambeau; Christophe Arnoult
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.